## Pharmacy and Therapeutics Committee Virtual Meeting

**January 19, 2022**  
**12:00 PM - 5:00 PM**

**Zoom Meeting Registration:**
To attend the meeting from a PC, Mac, iPad, iPhone, or Android device, please click on the URL below:  
[https://ahcccs.zoom.us/webinar/register/WN__7swQ37yT7y1-PKzB1_U1g](https://ahcccs.zoom.us/webinar/register/WN__7swQ37yT7y1-PKzB1_U1g)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
</tr>
</thead>
</table>
| 12:00 PM | **Welcome and Introductions:** Suzanne Berman, RPH, AHCCCS Pharmacy Director  
**P&T October 18, 2021 - Minutes Review and Vote** |
| 12:15 PM | **One Supplemental Rebate and Eighteen Non-Supplemental Rebate Class Reviews:**  
Clinical review by Sarah Martinez, PharmD, Magellan |
|       | 1. Androgenic Agents  
a. Public Testimony: None |
|       | 2. Antidepressants, Others  
a. Public Testimony: Written testimony received from  
i. Jasleen Chhatwal MD on behalf of the Arizona Psychiatric Society  
ii. Chiranjir Narine MD on behalf of District Medical Group |
|       | 3. Antidepressants, SSRIs  
a. Public Testimony: None |
|       | 4. Antivirals - Topical  
a. Public Testimony: None |
|       | 5. Bone Resorption Suppression Agents  
a. Public Testimony: None |
|       | 6. Bronchodilators, Beta Agonists  
a. Public Testimony: None |
|       | 7. Colony Stimulating Factors  
a. Public Testimony: None |
|       | 8. Enzyme Replacement, Gaucher Disease  
a. Public Testimony: None |
|       | 9. Erythropoiesis Stimulating Proteins  
a. Public Testimony: None |
|       | 10. Hypoglycemics, Alpha-Glucosidase Inhibitors  
a. Public Testimony: None |
11. Hypoglycemics, Metformins
   a. Public Testimony: None

12. Hypoglycemics, SGLT2s
   a. Public Testimony: None

13. Immune Globulins
   a. Public Testimony: None

14. Oral Oncology, Oral, Hematologic - Brand/Generic
   a. Public Testimony:
      i. Brukina written testimony received from Marjan Massoudi on behalf of Beigene

15. Ophthalmics, Anti-Inflammatory Products
   a. Public Testimony: None

16. Otic Antibiotics
   a. Public Testimony: None

17. Pulmonary Atrial Hypertension (PAH) Agents
   a. Public Testimony:
      i. Tyvaso written testimony received from Peter Barrio on behalf of United Therapeutics

18. Thrombopoiesis Stimulating Proteins
   a. Public Testimony: None

19. Ulcerative Colitis Agents
   a. Public Testimony: None

<table>
<thead>
<tr>
<th>1:50 PM</th>
<th>New Drug Reviews: Sarah Martinez, PharmD, Magellan</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Brand Name</strong></td>
<td><strong>Generic Name</strong></td>
</tr>
<tr>
<td>Azstarys</td>
<td>Serdeoxymethylphenidate &amp; Dexamethylphenidate</td>
</tr>
<tr>
<td>Bylvay</td>
<td>Odevixibat</td>
</tr>
<tr>
<td>Kerendia</td>
<td>Finerenone</td>
</tr>
<tr>
<td>Livmarli</td>
<td>Maralixibat</td>
</tr>
<tr>
<td>Livtencity</td>
<td>Maribvir</td>
</tr>
<tr>
<td>Lybalvi</td>
<td>Olanzapine &amp; Samidorphan</td>
</tr>
<tr>
<td>Opzelura</td>
<td>Ruxolitinib</td>
</tr>
<tr>
<td>Qulipta</td>
<td>Atogepant</td>
</tr>
<tr>
<td>Rezurock</td>
<td>Belumosudil</td>
</tr>
<tr>
<td>Skytrofa</td>
<td>Lonaparoctropin</td>
</tr>
<tr>
<td>Tavneos</td>
<td>Avacopan</td>
</tr>
<tr>
<td>Tryvaya Spray</td>
<td>Verenicline</td>
</tr>
</tbody>
</table>

| 2:15 PM | Break & Executive Session – Kristen Haloski, PharmD, AHAHVP, Magellan |
| 4:15 PM | Public Therapeutic Class Votes – Sarah Martinez, PharmD, Magellan |
| 4:45 PM | Biosimilar Update: None |
| 4:45 PM | Meeting Adjournment |

Future Meeting Dates: May 24, 2022, October 19, 2022